Investigation of complement component C4 copy number variation in human longevity

PLoS One. 2014 Jan 22;9(1):e86188. doi: 10.1371/journal.pone.0086188. eCollection 2014.

Abstract

Genetic factors have been estimated to account for about 25% of the variation in an adult's life span. The complement component C4 with the isotypes C4A and C4B is an effector protein of the immune system, and differences in the overall C4 copy number or gene size (long C4L; short C4S) may influence the strength of the immune response and disease susceptibilities. Previously, an association between C4B copy number and life span was reported for Hungarians and Icelanders, where the C4B*Q0 genotype, which is defined by C4B gene deficiency, showed a decrease in frequency with age. Additionally, one of the studies indicated that a low C4B copy number might be a genetic trait that is manifested only in the presence of the environmental risk factor "smoking". These observations prompted us to investigate the role of the C4 alleles in our large German longevity sample (∼ 700 cases; 94-110 years and ∼ 900 younger controls). No significant differences in the number of C4A, C4B and C4S were detected. Besides, the C4B*Q0 carrier state did not decrease with age, irrespective of smoking as an interacting variable. However, for C4L*Q0 a significantly different carrier frequency was observed in the cases compared with controls (cases: 5.08%; controls: 9.12%; p = 0.003). In a replication sample of 714 German cases (91-108 years) and 890 controls this result was not replicated (p = 0.14) although a similar trend of decreased C4L*Q0 carrier frequency in cases was visible (cases: 7.84%; controls: 10.00%).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Alleles
  • Complement C4 / genetics*
  • DNA Copy Number Variations*
  • Female
  • Gene Frequency
  • Genotype
  • Germany
  • Humans
  • Longevity / genetics*
  • Male
  • Middle Aged
  • Risk Factors
  • Young Adult

Substances

  • Complement C4

Grants and funding

This study was supported by the RESOLVE project (FP7-HEALTH-F4-2008-202047), the Excellence Cluster ‘Inflammation at Interfaces’ and the INTERREG 4 A programme Syddanmark-Schleswig-K.E.R.N (with EU funds from the European Regional Development Fund). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.